A conserved tryptophan at the membrane-water interface acts as a gatekeeper for Kir6.2/SUR1 channels and causes neonatal diabetes when mutated

Journal of Physiology

Volumn 589, Issue 13, 2011, Pages 3071-3083

  Männikkö, Roope ^a   Stansfeld, Phillip J ^a,b   Ashcroft, Alexandra S ^a   Hattersley, Andrew T ^c   Sansom, Mark S P ^a,b   Ellard, Sian ^c   Ashcroft, Frances M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; MEMBRANE PROTEIN; NEOMYCIN; SULFONYLUREA RECEPTOR 1; TOLBUTAMIDE; TRANSMEMBRANE DOMAIN 2 PROTEIN; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; WATER;

ANIMAL CELL; ARTICLE; CHANNEL GATING; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIABETES MELLITUS; DRUG ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE MUTATION; GENETICS; HETEROZYGOSITY; HUMAN; HUMAN CELL; IC 50; KCNJ11 GENE; NEWBORN; NEWBORN DIABETES MELLITUS; NEWBORN DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYTE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; XENOPUS;

AMINO ACID SEQUENCE; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CELL MEMBRANE; CHILD; CONSERVED SEQUENCE; DIABETES MELLITUS; FEMALE; HETEROZYGOTE DETECTION; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; MOLECULAR SEQUENCE DATA; MUTATION; OOCYTES; PHENOTYPE; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RATS; RECEPTORS, DRUG; TRYPTOPHAN; XENOPUS LAEVIS;

EID: 79959696154     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2011.209700     Document Type: Article

References (46)

1. Aguilar-Bryan L, Nichols CG, Wechsler SW, Clement JP 4th, Boyd AE 3rd, González G et al (1995). Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 268, 423-426.
2. ATP channel Kir6.2 subunit. EMBO J 24, 229-239.
3. Ashcroft FM (2007). The Walter B. Cannon physiology in perspective lecture, 2007. ATP-sensitive K-channels and disease: from molecule to malady. Am J Physiol Endocrinol Metab 293, E880-E889.
4. Ashcroft FM (2010). New uses for old drugs: neonatal diabetes and sulphonylureas. Cell Metab 11, 179-181.
5. Ashcroft FM, Harrison DE & Ashcroft SJH (1984). Glucose induces closure of single potassium channels in isolated rat pancreatic ß-cells. Nature 312, 446-448.
6. Babenko AP, Polak M, Cavé H, Busiah K, Czernichow P, Scharfmann R et al (2006). Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. New Engl J Med 355, 456-466.
7. ATP channel mutation. Science 329, 458-461.
8. ATP channel subunits. Neuron 18, 827-838.
9. Cohen M, Potapov V & Schreiber G (2009). Four distances between pairs of amino acids provide a precise description of their interaction. PLoS Comput Biol 5, e1000470.
10. de Wet H, Mikhailov MV, Fotinou C, Dreger M, Craig TJ, Vénien-Bryan C & Ashcroft FM (2007). Studies of the ATPase activity of the ABC protein SUR1. FEBS J 274, 3532-3544.
11. ATP channel inhibition by ATP. Biophys J 86, 2101-2112.
12. ATP channel inhibition by ATP requires distinct functional domains of the cytoplasmic C terminus of the pore-forming subunit. Proc Natl Acad Sci U S A 95, 13953-13958.
13. + channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes 56, 1930-1937.
14. Girard CA, Shimomura K, Proks P, Absalom N, Castano L, Perez de Nanclares G & Ashcroft FM (2006). Functional analysis of six Kir6.2 (KCNJ11) mutations causing neonatal diabetes. Pflugers Arch 453, 323-332.
15. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS et al (2004). Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. New Eng J Med 350, 1838-1849.
16. + currents expressed in Xenopus oocytes. J Physiol 498, 87-98.
17. Gribble FM & Reimann F (2003). Sulphonylurea action revisited: the post-cloning era. Diabetologia 46, 875-891.
18. Gribble FM, Tucker SJ & Ashcroft FM (1997b). The essential role of the Walker A motifs of SUR1 in K-ATP channel activation by Mg-ADP and diazoxide. EMBO J 16, 1145-1152.
19. ATP channel by interaction with its SUR1 subunit. Proc Natl Acad Sci U S A 95, 7185-7190.
20. Haider S, Tarasov A, Craig T, Sansom MSP & Ashcroft FM (2007). Identification of the PIP2-binding site on Kir6.2 by molecular modelling and functional analysis. EMBO J 26, 3749-3759.
21. Hattersley AT & Ashcroft FM (2005). Activating Mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights and new therapy. Diabetes 54, 2503-2513.
22. Koster JC, Cadario F, Peruzzi C, Colombo C, Nichols CG & Barbetti F (2008). The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy. J Clin Endocrinol Metab 93, 1054-1061.
23. Kuo A, Gulbis JM, Antcliff JF, Rahman T, Lowe ED, Zimmer J et al (2003). Crystal structure of the potassium channel KirBac1.1 in the closed state. Science 300, 1922-1926.
24. Long SB, Campbell EB & Mackinnon R (2005). Voltage sensor of Kv1.2: structural basis of electromechanical coupling. Science 5, 903-908.
25. ATP channel in glucose homeostasis in health and disease: more than meets the islet. J Physiol 588, 3201-3209.
26. ATP channel complex Kir6.2-SUR1. EMBO J 24, 4166-4175.
27. ATP channels as metabolic sensors in acute metabolic changes. J Mol Cell Cardiol 38, 917-925.
28. Mlynarski W, Tarasov AI, Gach A, Girard CA, Pietrzak I, Zubcevic L et al (2007). Improvement of CNS function with sulphonylurea treatment in intermediate DEND syndrome caused by the novel H46L mutation in the KCNJ11 gene. Nat Clin Prac Neurol 3, 640-645.
29. ATP channels as molecular sensors of cellular metabolism. Nature 440, 470-476.
30. Nichols CG, Shyng SL, Nestorowicz A, Glaser B, Clement JP 4th, Gonzalez G et al (1996). Adenosine diphosphate as an intracellular regulator of insulin secretion. Science 272, 1785-1787.
31. Nishida M, Cadene M, Chait BT & MacKinnon R (2007). Crystal structure of a Kir3.1-prokaryotic Kir channel chimera. EMBO J 26, 4005-4015.
32. Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B et al.; Neonatal Diabetes International Collaborative Group (2006). Switching from insulin to oral sulphonylureas patients with diabetes due to Kir6.2 mutations. New Eng J Med 355, 467-477.
33. Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT & Ashcroft FM (2004). Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci U S A 101, 17539-17544.
34. Proks P, Arnold AL, Bruining J, Girard C, Flanagan SE, Larkin B et al (2006). A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum Mol Genet 15, 1793-1800.
35. Sali A & Blundell TL (1993). Comparative protein modeling by satisfaction of spatial restraints. J Mol Biol 234, 779-815.
36. 2 site in the N terminus. J Biol Chem 278, 10500-10505.
37. Shimomura K, Hörster F, de Wet H, Flanagan SE, Ellard S, Hattersley AT et al (2007). A novel mutation causing DEND syndrome - a treatable channelopathy of pancreas and brain. Neurology 69, 1342-1349.
38. ATP channel activity by diazoxide and MgADP. Distinct functions of the two nucleotide-binding folds of the sulfonylurea receptor. J Gen Physiol 110, 643-654.
39. ATP channels. J Gen Physiol 116, 599-608.
40. Slingerland AS, Hurkx W, Noordam K, Flanagan SE, Jukema JW, Meiners LC et al (2008). Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. Diabet Med 25, 277-281.
41. Slingerland AS, Nuboer R, Hadders-Algra M, Hattersley AT & Bruining GJ (2006). Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia 49, 2559-2563.
42. 2-binding site in Kir channels: definition by multiscale biomolecular simulations. Biochemistry 48, 10926-10933.
43. + channel Kir2.2 at 3.1 Å resolution. Science 326, 1668-1674.
44. Tarasov AI, Girard CA, Larkin B, Tammaro P, Flanagan SE, Ellard S & Ashcroft FM (2007). Functional analysis of two Kir6.2 (KCNJ11) mutations, K170T and E322K, causing neonatal diabetes. Diabetes Obes Metab 9, 46-55.
45. Tarasov AI, Welters HJ, Senkel S, Ryffel GU, Hattersley AT, Morgan NG & Ashcroft FM (2006). A Kir6.2 mutation causing neonatal diabetes impairs electrical activity and insulin secretion from INS-1 beta cells. Diabetes 55, 3075-3082.
46. Tucker SJ, Gribble FM, Zhao C, Trapp S & Ashcroft FM (1997). Truncation of Kir6.2 produces ATP-sensitive K-channels in the absence of the sulphonylurea receptor. Nature 387, 179-183.